May 7 (Reuters) – Italy’s Angelini Pharma said on Thursday it has agreed to acquire Catalyst Pharmaceuticals for $4.1 billion.
The Italian drugmaker will pay $31.5 in cash for each share of Catalyst, which specialises in rare disease therapies.
The offer represents a 3% premium to Catalyst’s last closing price, according to data compiled by LSEG.
(Reporting by Ananya Palyekar in Bengaluru; Editing by Sumana Nandy)
Comments